Related Experiment Videos
Antitumor activity of some bacterial proteases: eradication of solid tumors in mice by intratumor injection
Cancer Research
|January 15, 1987
Abstract:
A protease isolated from the culture filtrate of a Gram-negative bacteria, Serratia marcescens kums 3958, showed very potent antitumor activity when injected into Meth-A or RL male 1 tumors in BALB/c mice at 30 micrograms per tumor or more. This and certain other proteases, which are resistant to many protease inhibitors in plasma, appear to be new candidate drugs for regional treatment of solid tumors.
Insights
A novel protease from Serratia marcescens demonstrated potent antitumor activity in mouse models. This enzyme, resistant to plasma inhibitors, shows promise as a new regional cancer therapy for solid tumors.
Area of Science:
- Biochemistry
- Microbiology
- Oncology
Background:
- The study investigates proteases derived from bacterial sources for potential therapeutic applications.
- Serratia marcescens is a Gram-negative bacterium known for producing various enzymes.
Purpose of the Study:
- To evaluate the antitumor activity of a protease isolated from Serratia marcescens kums 3958.
- To assess the potential of this protease as a candidate for regional solid tumor treatment.
Main Methods:
- Isolation and purification of a protease from the culture filtrate of Serratia marcescens kums 3958.
- In vivo testing of the isolated protease's efficacy against Meth-A or RL male 1 tumors in BALB/c mice.
Main Results:
- The isolated protease exhibited potent antitumor activity at doses of 30 micrograms per tumor or higher.
- The enzyme demonstrated resistance to common plasma protease inhibitors.
Conclusions:
- The protease from Serratia marcescens is a promising candidate for the regional treatment of solid tumors.
- Its resistance to plasma inhibitors suggests suitability for direct tumor site administration.